Actavis Sues Sandoz, Hetero Over Generic Prostate Drug

Law360, New York (June 19, 2013, 1:08 PM EDT) -- Kissei Pharmaceutical Co. Ltd. and Actavis Inc. said Monday in virtually identical suits filed in Delaware federal court that Sandoz Inc. and Hetero Labs Ltd. infringed a patent for their enlarged-prostate drug by seeking approval for generic forms of the treatment.

Sandoz and Hetero unlawfully filed abbreviated new drug applications with the U.S. Food and Drug Administration to market 4- and 8-milligram silodosin tablets before the expiration of the patent for Rapaflo, which is sold by Actavis subsidiary Watson Laboratories Inc., according to the suit....
To view the full article, register now.